World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
70
Citations
15035
World Ranking
2441
National Ranking
1166

Daniel A. Vallera publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Daniel A. Vallera sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 285 publications — 61st percentile

61% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Daniel A. Vallera D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Daniel A. Vallera sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 70 D-Index — 52nd percentile

52% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Daniel A. Vallera is affiliated with the University of Minnesota in the United States. Their research spans multiple fields, with a focus on medicine, immunology and microbiology, as well as biochemistry, genetics, and molecular biology. Their work often intersects with subfields such as immunology, oncology, pulmonary and respiratory medicine, hematology, and biotechnology.

The research topics Vallera has contributed to include:

  • Immune Cell Function and Interaction
  • CAR-T cell therapy research
  • Veterinary Oncology Research
  • Cancer Research and Treatments
  • Virus-based gene therapy research
  • T-cell and B-cell Immunology
  • Acute Myeloid Leukemia Research

Among their frequent collaborators are:

  • Martin Felices
  • Jaime F. Modiano
  • Jeffrey S. Miller
  • Sara Pracht
  • Antonella Borgatti

Their publications appear predominantly in journals such as Hematological Oncology, Regular and Young Investigator Award Abstracts, Cancer Research, Blood Advances, and Cancers. These venues reflect their concentration on clinical and experimental studies in hematology, oncology, and immunology.

Notable recent publications by Daniel A. Vallera include:

  • "A trispecific killer engager molecule against CLEC12A effectively induces NK-cell mediated killing of AML cells" (2020, Leukemia)
  • "Delineation of target expression profiles in CD34+/CD38− and CD34+/CD38+ stem and progenitor cells in AML and CML" (2020, Blood Advances)
  • "NK-Cell-Mediated Targeting of Various Solid Tumors Using a B7-H3 Tri-Specific Killer Engager In Vitro and In Vivo" (2020, Cancers)
  • "Potent Cytolytic Activity and Specific IL15 Delivery in a Second-Generation Trispecific Killer Engager" (2020, Cancer Immunology Research)
  • "Anti-NKG2C/IL-15/anti-CD33 killer engager directs primary and iPSC-derived NKG2C+ NK cells to target myeloid leukemia" (2021, Molecular Therapy)

Their research often centers on immunotherapy approaches, particularly involving natural killer (NK) cells and killer engagers, with applications in acute myeloid leukemia (AML), chronic myeloid leukemia (CML), and solid tumors.

Best Publications

  • Comparison of autologous and allogeneic bone marrow transplantation for treatment of high-risk refractory acute lymphoblastic leukemia.

    John H. Kersey;Daniel Weisdorf;Mark E. Nesbit;Tucker W. LeBien

  • In vivo blockade of CD28/CTLA4: B7/BB1 interaction with CTLA4-Ig reduces lethal murine graft-versus-host disease across the major histocompatibility complex barrier in mice

    Bruce R Blazar;Patricia A. Taylor;Peter S. Linsley;Daniel A Vallera

  • IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function

    Daniel A. Vallera;Martin Felices;Ron McElmurry;Valarie McCullar

  • Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia.

    Qing Zhou;Meghan E. Munger;Steven L. Highfill;Jakub Tolar

  • CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets.

    Michelle K. Gleason;Julie A. Ross;Erica D. Warlick;Troy C. Lund

  • Differential effects of the absence of interferon-gamma and IL-4 in acute graft-versus-host disease after allogeneic bone marrow transplantation in mice.

    William J Murphy;Lisbeth A. Welniak;Dennis D. Taub;Robert H. Wiltrout

  • 3D Bioprinted In Vitro Metastatic Models via Reconstruction of Tumor Microenvironments.

    Fanben Meng;Carolyn M. Meyer;Daeha Joung;Daniel A. Vallera

  • Targeting natural killer cells to acute myeloid leukemia in vitro with a CD16 x 33 bispecific killer cell engager and ADAM17 inhibition

    Andres Wiernik;Bree Foley;Bin Zhang;Michael R. Verneris

  • Bispecific and Trispecific Killer Cell Engagers Directly Activate Human NK Cells through CD16 Signaling and Induce Cytotoxicity and Cytokine Production

    Michelle K. Gleason;Michael R. Verneris;Deborah A. Todhunter;Bin Zhang

  • Ex-vivo treatment of donor bone marrow with anti-T-cell immunotoxins for prevention of graft-versus-host disease.

    A.H Filipovich;A.H Filipovich;R.J Youle;R.J Youle;D.M Neville;D.M Neville;D.A Vallera;D.A Vallera

  • Blockade of CD40 ligand-CD40 interaction impairs CD4+ T cell-mediated alloreactivity by inhibiting mature donor T cell expansion and function after bone marrow transplantation.

    Bruce R. Blazar;Patricia A. Taylor;Angela Panoskaltsis-Mortari;Janet Buhlman

  • Anti-T-cell reagents for human bone marrow transplantation: ricin linked to three monoclonal antibodies

    Daniel A. Vallera;Robert C. Ash;Esmail D. Zanjani;John H. Kersey

  • Keratinocyte Growth Factor Administered Before Conditioning Ameliorates Graft-Versus-Host Disease After Allogeneic Bone Marrow Transplantation in Mice

    Angela Panoskaltsis-Mortari;Angela Panoskaltsis-Mortari;David L. Lacey;David L. Lacey;Daniel A. Vallera;Daniel A. Vallera;Bruce R. Blazar;Bruce R. Blazar

  • Interleukin-10 administration decreases survival in murine recipients of major histocompatibility complex disparate donor bone marrow grafts.

    Bruce R. Blazar;Patricia A. Taylor;Sidney Smith;Daniel A. Vallera

  • Recent advances in graft-versus-host disease (GVHD) prevention

    Bruce R. Blazar;Robert Korngold;Daniel A. Vallera

  • Opposing Roles of CD28:B7 and CTLA-4:B7 Pathways in Regulating In Vivo Alloresponses in Murine Recipients of MHC Disparate T Cells

    Bruce R. Blazar;Patricia A. Taylor;Angela Panoskaltsis-Mortari;Arlene H. Sharpe

  • Use of a novel colony assay to evaluate the cytotoxicity of an immunotoxin containing pokeweed antiviral protein against blast progenitor cells freshly obtained from patients with common B-lineage acute lymphoblastic leukemia.

    Fatih M. Uckun;Kazimiera J. Gajl-Peczalska;John H. Kersey;Lou L. Houston

  • Infusion of anti-B7.1 (CD80) and anti-B7.2 (CD86) monoclonal antibodies inhibits murine graft-versus-host disease lethality in part via direct effects on CD4+ and CD8+ T cells.

    Bruce R. Blazar;Arlene H. Sharpe;Patricia A. Taylor;Angela Panoskaltsis-Mortari

  • Coblockade of the LFA1:ICAM and CD28/CTLA4:B7 pathways is a highly effective means of preventing acute lethal graft-versus-host disease induced by fully major histocompatibility complex-disparate donor grafts

    Bruce R. Blazar;Patricia A. Taylor;Angela Panoskaltsis-Mortari;Gary S. Gray

  • THE CRITICAL EARLY PROINFLAMMATORY EVENTS ASSOCIATED WITH IDIOPATHIC PNEUMONIA SYNDROME IN IRRADIATED MURINE ALLOGENEIC RECIPIENTS ARE DUE TO DONOR T CELL INFUSION AND POTENTIATED BY CYCLOPHOSPHAMIDE

    A Panoskaltsis-Mortari;P A Taylor;T M Yaeger;O D Wangensteen

Frequent Co-Authors

Bruce R. Blazar
Bruce R. Blazar University of Minnesota
Patricia A. Taylor
Patricia A. Taylor University of Minnesota
Jeffrey S. Miller
Jeffrey S. Miller University of Minnesota
Angela Panoskaltsis-Mortari
Angela Panoskaltsis-Mortari University of Minnesota
Daniel J. Weisdorf
Daniel J. Weisdorf University of Minnesota
John H. Kersey
John H. Kersey University of Minnesota
Fatih M. Uckun
Fatih M. Uckun University of Southern California
Norma K.C. Ramsay
Norma K.C. Ramsay University of Minnesota
Michael R. Verneris
Michael R. Verneris University of Colorado Denver
Jaime F. Modiano
Jaime F. Modiano University of Minnesota

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in pursuing Immunology in the USA, exploring related online degrees and career pathways can be highly beneficial. Many students in the healthcare field begin their journey through nursing programs, which offer various accelerated options for quicker entry into the profession.

One popular route is through accelerated rn to np programs. These programs allow registered nurses to fast-track their education and become nurse practitioners with advanced clinical knowledge—skills that are valuable in immunology-related healthcare settings.

For individuals without a prior nursing background, online absn programs for non nurses provide a direct pathway into nursing. These degrees offer flexible learning options and prepare students for foundational roles in patient care and research.

Additionally, some may benefit from exploring 12-month accelerated nursing programs, which deliver comprehensive nursing education within a short timeframe. These intensive programs are designed to meet high demand for nursing professionals in healthcare and research fields.

Those seeking entry-level positions might consider easy admission lpn programs. Licensed Practical Nurse programs are often more accessible and can serve as a stepping stone toward advanced roles in immunology-related care and study.

Best Scientists Citing Daniel A. Vallera

Trending Scientists

Recently Published Articles